Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

The procedure of pharmacist consultations during the first and the monthly follow-up sessions.

More »

Fig 1 Expand

Table 1.

Drug-Related Problem (DRP) classification and their underlying cause [41].

More »

Table 1 Expand

Table 2.

Grouping of interactions based on the prescribing and dispensing category of the medicine, and on which healthcare professional is competent to provide the necessary intervention and a complete solution.

More »

Table 2 Expand

Table 3.

Grouping of interactions from a clinical risk perspective based on UptoDate Lexicomp® interaction database [43].

More »

Table 3 Expand

Table 4.

Definitions of pharmacist interventions to solve drug-related problems.

More »

Table 4 Expand

Table 5.

Characteristics of patients surveyed.

More »

Table 5 Expand

Fig 2.

The distribution and order of occurrence of the underlying causes of drug-related problems.

DRP: Drug-Related Problem; n(DRP) = 984.

More »

Fig 2 Expand

Fig 3.

Frequency of interaction risks grouped by the competent healthcare professional providing the necessary intervention and a complete solution, and by the prescribing and dispensing category of the drugs involved.

Rx: Prescription drug; OTC: Over-the-counter medicine; Other: Other products (e.g. dietary supplements); n.a.: Not available; n = 531.

More »

Fig 3 Expand

Fig 4.

Distribution of interactions by UpToDate Lexiomp® risk classification grades [43].

A: No known interaction, B: No action needed, C: Monitor therapy, D: Consider therapy modification, X: Avoid combination; n.a.: Not available; n = 531.

More »

Fig 4 Expand

Fig 5.

Distribution of interactions by clinical risk caused by active substances causing the most Grade A/B or Grade D/X interactions.

5/A: Distribution of interactions by clinical risk caused by active substances causing the most Grade A/B interactions. 5/B: Distribution of interactions by clinical risk caused by active substances causing the most Grade D/X interactions. A: No known interaction; B: No action needed; C: Monitor therapy; D: Consider therapy modification; X: Avoid combination; n.a.: Not available.

More »

Fig 5 Expand

Table 6.

Grade D or X interaction pairs of the three most common D or X interacting agents (acenocoumarol, acetylsalicylic acid, and diclofenac).

More »

Table 6 Expand

Fig 6.

The incidence of pharmacist interventions to solve interaction risks, in order of frequency.

GP: General practitioner; n = 599.

More »

Fig 6 Expand

Fig 7.

Proposal for a uniform pharmacy procedure for the management of interaction risks.

More »

Fig 7 Expand